Efficacy and Safety of Lobeglitazone Versus Sitagliptin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 248 participants.
Also called NCT02480465
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 248 participants
- Registry
-
NCT02480465
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT02480465. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Lobeglitazone Versus Sitagliptin
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Lobelitazone 0.5mg
- Intervention (Drug)
- Sitagliptin 100mg
- Lead sponsor
- Chong Kun Dang Pharmaceutical
Record details
- Record id
cardio:ct-nct02480465- Content hash
df773669b682eb132b264c33d03ad1095476f16607d32fce4ce0ef2af570c2f8